TY - JOUR
T1 - A novel human cellular model of CDA IV enables comprehensive analysis revealing the molecular basis of the disease phenotype
AU - Ferrer-Vicens, Ivan
AU - Ferguson, Daniel C.J.
AU - Wilson, Marieangela C.
AU - Heesom, Kate J.
AU - Bieker, James J.
AU - Frayne, Jan
N1 - Funding Information:
This study was funded by the Medical Research Council ( MR/R009341/1 ) and National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grant ( R01 DK046865 ).
Funding Information:
The authors thank Phil Lewis, of the School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom for assistance with analyzing mass spectrometry data and producing figures; Andrew Herman of the University of Bristol Flow Cytometry Facility for cell sorting and use of equipment, Maurice A. Canham of the Scottish National Blood Transfusion Service, Edinburgh and the Wellcome Trust Clinical Research Facility at the University of Edinburgh, United Kingdom for performing molecular karyotyping; Belinda Singleton of Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant, Bristol, United Kingdom; and Winnie Lau of School of Biochemistry, University of Bristol, United Kingdom for creating the constructs used for luciferase assay and for setting up the luciferase assay system. IBGRL antibodies were kindly supplied by Jonathan Dixey, IBGRL, Filton, Bristol, United Kingdom. The KLF1 ChIPseq data for human erythroid cells was kindly provided by Avik Choudhuri and Leonard Zon of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA. This study was funded by the Medical Research Council (MR/R009341/1) and National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grant (R01 DK046865). Contribution: I.F.-V. and D.C.J.F. contributed equally to the work; J.F. conceived and supervised the study; J.F. I.F.-V. and D.C.J.F designed the experiments; I.F-V. and D.C.J.F generated the KLF1+/E325K and KLF1+/− cell lines; D.C.J.F. and I.F.-V. conducted the majority of experiments, analyzed data, and prepared figures; J.F. analyzed data; J.J.B. assisted with data analysis and discussion; M.C.W. carried out the globin high-performance liquid chromatography experiments; M.C.W. and K.J.H. performed TMT labeling, mass spectrometry, and data acquisition, and contributed to proteomics analysis; J.F. wrote the manuscript; and D.C.J.F. I.F.-V. and J.J.B. edited the manuscript.
Publisher Copyright:
© 2023 The American Society of Hematology
PY - 2023/6/22
Y1 - 2023/6/22
N2 - Red blood cell disorders can result in severe anemia. One such disease congenital dyserythropoietic anemia IV (CDA IV) is caused by the heterozygous mutation E325K in the transcription factor KLF1. However, studying the molecular basis of CDA IV is severely impeded by the paucity of suitable and adequate quantities of material from patients with anemia and the rarity of the disease. We, therefore, took a novel approach, creating a human cellular disease model system for CDA IV that accurately recapitulates the disease phenotype. Next, using comparative proteomics, we reveal extensive distortion of the proteome and a wide range of disordered biological processes in CDA IV erythroid cells. These include downregulated pathways the governing cell cycle, chromatin separation, DNA repair, cytokinesis, membrane trafficking, and global transcription, and upregulated networks governing mitochondrial biogenesis. The diversity of such pathways elucidates the spectrum of phenotypic abnormalities that occur with CDA IV and impairment to erythroid cell development and survival, collectively explaining the CDA IV disease phenotype. The data also reveal far more extensive involvement of KLF1 in previously assigned biological processes, along with novel roles in the regulation of intracellular processes not previously attributed to this transcription factor. Overall, the data demonstrate the power of such a model cellular system to unravel the molecular basis of disease and how studying the effects of a rare mutation can reveal fundamental biology.
AB - Red blood cell disorders can result in severe anemia. One such disease congenital dyserythropoietic anemia IV (CDA IV) is caused by the heterozygous mutation E325K in the transcription factor KLF1. However, studying the molecular basis of CDA IV is severely impeded by the paucity of suitable and adequate quantities of material from patients with anemia and the rarity of the disease. We, therefore, took a novel approach, creating a human cellular disease model system for CDA IV that accurately recapitulates the disease phenotype. Next, using comparative proteomics, we reveal extensive distortion of the proteome and a wide range of disordered biological processes in CDA IV erythroid cells. These include downregulated pathways the governing cell cycle, chromatin separation, DNA repair, cytokinesis, membrane trafficking, and global transcription, and upregulated networks governing mitochondrial biogenesis. The diversity of such pathways elucidates the spectrum of phenotypic abnormalities that occur with CDA IV and impairment to erythroid cell development and survival, collectively explaining the CDA IV disease phenotype. The data also reveal far more extensive involvement of KLF1 in previously assigned biological processes, along with novel roles in the regulation of intracellular processes not previously attributed to this transcription factor. Overall, the data demonstrate the power of such a model cellular system to unravel the molecular basis of disease and how studying the effects of a rare mutation can reveal fundamental biology.
UR - http://www.scopus.com/inward/record.url?scp=85160070170&partnerID=8YFLogxK
U2 - 10.1182/blood.2022018735
DO - 10.1182/blood.2022018735
M3 - Article
C2 - 37084386
AN - SCOPUS:85160070170
SN - 0006-4971
VL - 141
SP - 3039
EP - 3054
JO - Blood
JF - Blood
IS - 25
ER -